Home › NDC Lookup › RxCUI directory › RxCUI 198285

Timolol 20 MG Oral Tablet — RxCUI 198285

RxNorm drug concept · Semantic clinical drug
RxCUI 198285 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI198285
Official nameTimolol 20 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known astimolol 20 MG (as maleate) Oral Tablet; timolol maleate 20 MG Oral Tablet
FDA products mapped4
Package NDCs mapped4
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Timolol Ophthalmic: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It's lowering the pressure inside your eye. Your eye constantly makes a fluid called aqueous humor, and if that fluid builds up too fast, pressure rises and can damage your optic n...
  • What is timolol eye drops actually doing for my eyes?
  • You're right, it has a slightly different consistency. Before each use, flip the closed bottle upside down and give it one shake — just once is enough. Then apply one drop into the...
  • How do I use the gel-forming version correctly? It seems thicker than regular drops.
📖 Read our full Timolol Ophthalmic guide →

🕸️ Concept Web — How Timolol 20 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Timolol 20 MG Oral Tablet RxCUI 198285

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Timolol 10600
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Timolol Oral Tablet 374135
    • Timolol Oral Product 1157101
    • Timolol Pill 1157086
    • Oral Tablet 317541
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Timolol 20 MG 328746

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Timolol 20 MG SCDC · 328746
  • Timolol Oral Tablet SCDF · 374135
  • Timolol Oral Product SCDG · 1157101
  • Timolol Pill SCDG · 1157086

📦 FDA Products & Package NDCs

4 products · 4 package NDCs
4 package NDCs map to RxCUI 198285 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00378-0221-01 100 TABLET in 1 BOTTLE, PLASTIC (0378-0221-01) Timolol Maleate Mylan Pharmaceuticals Inc. 1990-06-08
16571-0223-01 100 TABLET in 1 BOTTLE (16571-223-01) Timolol Maleate Rising Pharma Holdings, Inc. 2024-12-10
16571-0224-01 100 TABLET in 1 BOTTLE (16571-224-01) Timolol Maleate Rising Pharma Holdings, Inc. 2024-12-10
16571-0225-01 100 TABLET in 1 BOTTLE (16571-225-01) Timolol Maleate Rising Pharma Holdings, Inc. 2024-12-10
Observed labelers: Rising Pharma Holdings, Inc. (3) · Mylan Pharmaceuticals Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.